Hormone-free option
Safety focused
Women’s Health Clinic FAQ
How many sessions of intimate polynucleotides are needed?
Intimate polynucleotides are non-hormonal biostimulatory treatments used in some clinics for vulvovaginal tissue quality. The important first step is confirming the symptom cause, not choosing an injectable by name.
Direct answer
There is no single correct number of intimate polynucleotide sessions. Some competitor protocols describe a short course followed by maintenance, but the plan should be individual and based on diagnosis, symptom severity, tissue findings, product choice, response and safety factors. A resolved package should not be sold before checking infection, bleeding, pregnancy, fish allergy, cancer history and pain causes. Reassessment matters more than repeating treatment automatically.
Your clinician should review symptoms, medical history, allergies, medicines, cancer history where relevant, alternatives, expected benefits, limitations and aftercare before deciding whether treatment fits.
Educational only. Suitability must be confirmed after consultation and assessment. Results vary. Not a cure.
At a glance
These are the main points to understand before deciding whether intimate polynucleotides are suitable.
Polynucleotides at a glance
Non-hormonal biostimulation
Core Ingredients
Formulations like NewGyn® combine Polynucleotides (PN-HPT®) with non-crosslinked Hyaluronic Acid (HA) and Mannitol.
Mechanism of Action
Polynucleotides activate fibroblast cells to produce new collagen and elastin, while Hyaluronic Acid provides deep hydration.
Key point 3
Mannitol protects the HA from rapid enzymatic degradation and oxidative stress.
Angiogenesis
The treatment promotes the formation of healthy new micro-blood vessels, improving localised circulation and tissue oxygenation.
Important safety note
Contraindications: This treatment is strictly contraindicated for individuals who are pregnant, breastfeeding, undergoing IVF, or have an active genital infection (such as active Herpes Simplex).
Allergy
Evidence
Aftercare
Alternatives
Detailed answer
Session number is individual
Course length depends on symptoms, tissue findings, safety factors and response.
Do not sell packages first
A resolved course should not replace diagnosis, consent and reassessment.
Evidence
Symptoms
Alternatives
What it means
Efficacy Rates: A 2019 prospective cohort study by Palmieri and Raichi evaluated postmenopausal women with confirmed vulvovaginal atrophy.
Why symptoms matter
Symptom Reduction: By day 90 of the protocol, patients experienced a 59% to 76% reduction in major symptoms compared to baseline.
Evidence limits
Evidence is encouraging in selected areas, but intimate-use claims should remain cautious and assessment-led.
Treatment fit
Treatment Duration: The clinical procedure is rapid, typically taking only 10 to 20 minutes to complete.
What this means in practice
Treatment Duration: The clinical procedure is rapid, typically taking only 10 to 20 minutes to complete.
Session Quantity: A standard initial induction protocol requires 3 to 5 sessions.
Patient safety
Why diagnosis comes first
Many intimate symptoms overlap. The right treatment depends on whether the issue is GSM, infection, vulval skin disease, scarring, pelvic-floor guarding, medication effect or another cause.
It checks the cause
Efficacy Rates: A 2019 prospective cohort study by Palmieri and Raichi evaluated postmenopausal women with confirmed vulvovaginal atrophy.
It protects safety
Contraindications: This treatment is strictly contraindicated for individuals who are pregnant, breastfeeding, undergoing IVF, or have an active genital infection (such as active Herpes.
It reviews alternatives
Moisturisers, lubricants, local ooestrogen, pelvic-floor care or specialist review may be more appropriate first.
It sets expectations
Polynucleotides are gradual tissue-support treatments, not instant resolves or promised outcomes.
Non-hormonal does not mean automatic
A hormone-free option may still be unsuitable if there is infection, unexplained bleeding, pregnancy, recent surgery, severe fish allergy or unclear pelvic pain.
Good care explains product source, treatment route, alternatives, limits, aftercare and when another medical pathway is safer.
Considerations
What to consider
Treatment planning should include diagnosis, symptom pattern, allergy risk, medicines, consent, realistic timelines and aftercare.
Consultation priorities
A consultation should review symptoms, medical history, fish allergy, infection risk, bleeding risk, pregnancy status, expectations and alternatives.
Consent
Aftercare
Review
Before treatment
Consultation: The journey begins with a thorough medical history review to rule out contraindications and align aesthetic and functional expectations.
During care
Preparation & Comfort: On the day of treatment, the area is cleansed and a topical anaesthetic (numbing cream) is applied for roughly 30 minutes to minimise discomfort.
Aftercare
Administration: The clinician uses a very fine needle to deliver precise micro-droplet intradermal injections of the polynucleotide gel across targeted areas of the vulva and labia.
When to reassess
If symptoms persist, worsen or do not match expectations, reassessment is safer than repeating treatment automatically.
Practical expectations
Session Quantity: A standard initial induction protocol requires 3 to 5 sessions.
Costs and treatment plans should be confirmed before booking; do not rely on generic package claims.
Common concerns and myths
Common misconceptions
Clear patient information should correct over-simple claims and keep expectations realistic.
Myth: polynucleotides are fillers
Reality: they are biostimulatory DNA fragments used for gradual tissue-quality support, not instant volume.
Myth: hormone-free means suitable for everyone
Reality: fish allergy, infection, bleeding, pregnancy, recent surgery and unclear pain can make treatment unsuitable.
Myth: results are promised
Reality: response varies and should be reviewed before repeating treatment.
Evidence and limits
Mechanism-of-action language should not be treated as proof of a predictable result.
Alternatives still matter
Moisturisers, local hormonal care, pelvic-floor physiotherapy, infection treatment or specialist review may be better for some patients.
Safety checklist
Safety checklist
Use these questions to decide whether treatment should be discussed, delayed or redirected.
Has the cause been assessed?
Symptoms should be reviewed in context before selecting an injectable treatment.
Are red flags absent?
Active infection, unexplained bleeding, severe pain or new vulval changes should be checked first.
Are alternatives clear?
Ask what conservative, hormonal, pelvic-floor or specialist options may be more appropriate.
Is follow-up planned?
The clinic should explain aftercare, review timing and when to seek help.
Reassuring signs
Proceeding is more reasonable when diagnosis is clear, goals are realistic, red flags are absent and aftercare is understood.
No red flags
Review plan
Reasons to pause
Pause treatment for active infection, unexplained bleeding, pregnancy, severe fish allergy, recent pelvic surgery, severe pain or changing vulval skin.
Bleeding
Infection
When to escalate
When to seek medical help
Some symptoms should be assessed before any elective intimate treatment. Use NHS 111 online
Allergy symptoms
Swelling of the lips, tongue or face, breathing difficulty, widespread hives, faintness or collapse needs urgent help.
Bleeding or new skin change
New post-menopausal bleeding, ulcers, changing white plaques, unusual discharge or visible blood in urine should be assessed.
Infection signs
Fever, pus, spreading redness, worsening swelling or feeling unwell after a procedure needs prompt advice.
Emergency symptoms
Call 999 in a life-threatening emergency, including collapse, chest pain or breathing difficulty.
Use NHS 111 for urgent advice or call 999 in a life-threatening emergency. This page is educational and does not replace individual medical assessment.
Regulatory resources
Authoritative resources
These sources support assessment-led, evidence-aware patient information and help separate clinical care from promotional claims.
PubMed: PN/HA intradermal treatment for vulvovaginal atrophy
This pilot study is directly relevant to PN/HA use in vulvovaginal atrophy and supports cautious evidence-aware discussion.
NICE menopause recommendations
NICE provides UK guidance for GSM, vaginal ooestrogen, non-hormonal care and cancer-history decision-making.
NHS guidance on allergies
NHS allergy guidance supports screening and urgent escalation language for fish-derived products.
Next step
Book a clinical consultation
A consultation can confirm whether intimate polynucleotides may be suitable, whether another pathway should come first, and what realistic outcomes, risks and aftercare would look like.
▶ View Research Sources (12 Sources)
These 12 source names are selected from 24 display-ready sources, with a raw audit trail of 46 imported records. Additional reviewed material included clinical papers, guidance documents and patient-facing medical resources; duplicate, low-relevance and non-clinical records were removed before display.
Educational only. This information is for education only and is not a substitute for professional medical advice, diagnosis or treatment. Results vary. Not a cure.
